Clinical Trial

Identification of an Immune Single Cell Transcriptomic Profile of Responder and Non-responder Hepatocellular Carcinoma Patients Treated With Immune-checkpoint Inhibitors

Study acronym: HCC RNA-seq
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 9, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The study aims to analyze blood samples from patients with advanced hepatocellular carcinoma who are receiving systemic treatment with immunotherapy. The objective is to determine whether treatment exposure leads to changes in the transcriptomic patterns of peripheral blood mononuclear cells (PBMCs), if these changes are associated with treatment response, and whether certain pre-treatment transcriptomic signatures can predict response to treatment. As an exploratory objective, PBMCs derived from patients exposed to immune checkpoint inhibitors will be co-cultured with their paired tumor cells in organoid cultures. This aims to assess whether these preclinical 3D models correlate with clinical outcomes.
Trial Details
NCT Number NCT07273708
Lead Sponsor Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions Advanced HCC Treated by Systemic Immunotherapy
Enrollment 20 participants
Start Date 2025-03-15
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-09